Prostacyclin, thromboxane and prostaglandin F2 alpha in suction blister fluid of human skin: effect of systemic aspirin and local glucocorticosteroid treatment.
D015121:6-Ketoprostaglandin F1 alpha / Q000378:metabolism; D000328:Adult; D001241:Aspirin / Q000494:pharmacology*; D001623:Betamethasone / Q000031:analogs & derivatives*; D001768:Blister / Q000378:metabolism*; D002990:Clobetasol / Q000031:analogs & derivatives* / Q000494:pharmacology; D015237:Dinoprost / Q000031:analogs & derivatives*; D011464:Epoprostenol / Q000378:metabolism*; D005122:Exudates and Transudates / Q000378:metabolism; D006801:Humans; D008297:Male; D011453:Prostaglandins / Q000378:metabolism*; D011460:Prostaglandins F / Q000378:metabolism*; D012867:Skin / Q000378:metabolism*; D013928:Thromboxane A2 / Q000378:metabolism*; D013929:Thromboxane B2 / Q000378:metabolism; D013931:Thromboxanes / Q000378:metabolism*
D011453:Prostaglandins; D011460:Prostaglandins F; D013931:Thromboxanes; C008228:15-keto-13,14-dihydroprostaglandin F2alpha; D013929:Thromboxane B2; D013928:Thromboxane A2; D015121:6-Ketoprostaglandin F1 alpha; D001623:Betamethasone; D002990:Clobetasol; D015237:Dinoprost; D011464:Epoprostenol; D001241:Aspirin; C100006:prostaglandin F1